Therapeutic Potential of Phytochemicals in Retinoblastoma: Comprehensive Review

Background: Retinoblastoma is the most common primary intraocular malignancy in children and is primarily caused by biallelic inactivation of the RB1 tumour suppressor gene, leading to dysregulation of the cell cycle. Despite advances in multimodal treatment approaches such as systemic and intra-arterial chemotherapy, focal therapies, radiotherapy, and enucleation, current treatment strategies remain limited due to significant systemic and ocular toxicities, chemoresistance, and suboptimal eye and vision preservation, particularly in resource-limited settings. Aim: The present review aims to evaluate the therapeutic potential of phytoconstituents in the management of retinoblastoma and to highlight their role as safer, multi-target anticancer agents in paediatric ocular oncology. Methods: Literature search was conducted using various databases like PubMed, Google Scholar and Web of Science with keywords like retinoblastoma, RB1, genetics, signalling pathways and phytochemicals having anticancer properties. Discussion: Phytochemicals play an anticancer role in retinoblastoma through various signalling pathways like NF-?B, CDK, JAK/STAT MAPK/ERK and PI3K/AKT/mTOR. The phytochemicals show various activities like pro-apoptotic, anti-angiogenic and anti-invasive properties. Conclusion: Phytoconstituents represent promising adjuncts or alternatives to conventional retinoblastoma therapies. However, further preclinical and clinical investigations are required to overcome formulation challenges such as ocular barriers and poor solubility, and to translate these natural compounds into effective therapeutic strategies. Major Finding: Phytochemicals show promise in retinoblastoma by targeting multiple oncogenic pathways with low toxicity, making them potential candidates for drug development. Their ability to induce apoptosis, inhibit tumour progression, and enhance therapeutic efficacy further supports their potential as safer, more effective alternatives for retinoblastoma

View article page

Download PDF